Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 4

recruiting
3 967
countries
28
conditions
2 124

10 514 trials match your criteria

Narcolepsy

Recruiting

Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680

Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:MH002

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:LY4268989 adipic acid

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa

Crohn's disease

Recruiting

Study of mirikizumab versus azathioprine in newly diagnosed moderate-to-severe Crohn’s disease patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:PF-07275315
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.